NAPS2 Neuroimaging Core

NAPS2 神经影像核心

• 批准号: 10674049
• 负责人: KEJAL KANTARCI
• 金额: $ 53.77万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674049
• 关键词: 3-Dimensional; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Atrophic; Brain Stem; Brain imaging; Cell Nucleus; Clinical; Clinical Data; Clinical Research; Collaborations; Collection; Communities; Confidentiality of Patient Information; Corpus striatum structure; Cross-Sectional Studies; Data; Data Collection; Data Set; Dementia with Lewy Bodies; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Disease Progression; Drug Delivery Systems; Ensure; Foundations; Functional Magnetic Resonance Imaging; Functional disorder; Funding; Future; Genetic; Goals; Image; Imaging Device; Investigation; Iron; Laboratories; Language; Longitudinal Studies; Magnetic Resonance Imaging; Maintenance; Maps; Measurement; Measures; Methods; Monitor; Multiple System Atrophy; Nerve Degeneration; Neurodegenerative Disorders; Office of Administrative Management; Outcome; Parasomnias; Parkinson Disease; Participant; Patients; Pattern; Play; Predisposition; Process; Protocols documentation; Quality Control; REM Sleep Behavior Disorder; Radionuclide Imaging; Reproducibility; Research; Research Personnel; Resolution; Resources; Rest; Role; Scanning; Site; Standardization; Substantia nigra structure; Symptoms; Techniques; Testing; Thick; Time; United States National Institutes of Health; Work; basal forebrain; biomarker identification; candidate marker; cerebral atrophy; clinical care; data management; data sharing; dopamine system; experience; genetic information; high risk; image processing; imaging modality; imaging study; innovation; interest; locus ceruleus structure; longitudinal analysis; multimodality; neuroimaging; neuroimaging marker; neuromelanin; neuroprotection; pars compacta; programs; progression marker; prospective; single photon emission computed tomography; sound; synucleinopathy; targeted biomarker; targeted treatment; trial design; uptake; web site

ABSTRACT: NAPS2 NEUROIMAGING CORE The Neuroimaging Core of the North American Prodromal Synucleinopathy Consortium on RBD, Stage 2 (NAPS2) will ensure that state-of-the-art techniques are applied and that innovative analytic techniques are used. The Neuroimaging Core will be directed by leaders in brain imaging in neurodegenerative diseases with extensive experience supporting the imaging needs of multi-site projects. Many of the Core leaders have collaborated with NAPS investigators on prior research in RBD and synucleinopathies. The prior experience and collaborations within the Neuroimaging Core team will ensure a smooth transition of imaging support for NAPS2. Prior imaging studies of RBD are few and have generally been small, retrospective, or single-site investigations. We provide preliminary data to support all of the imaging modalities that will be utilized in the protocol and demonstrate the soundness of the methods proposed. We will prospectively collect and evaluate multimodal MRI and DaTscan imaging data in over 300 participants with RBD longitudinally, at two time points, with innovative methods to support the Project and advance the field. There are several innovative aspects of this Core, including the use of: 1) multi-shell and multi-band imaging acquisition protocols for collection of high resolution dMRI and rs-fMRI data in reasonable acquisition time, harmonized across multiple sites, 2) quantification of iron load with multi-echo gradient echo (GRE) MRI using quantitative susceptibility mapping and R2* relaxometry, 3) quantification of neuromelanin volume in locus coeruleus and substantia nigra pars compacta using a magnetization transfer contrast neuromelanin-sensitive MRI (NM-MRI) approach with automated image processing and high reproducibility, and 4) DaTscan quantitative analysis using semi-automated processing to provide standardized and harmonized region-to-background and z-score data. The Neuroimaging Core aims are to: 1) establish and maintain harmonized MRI and DaTscan SPECT acquisition protocols at the participating sites, 2) operate a standardized quality control program for MRI and DaTscan, including ongoing image quality monitoring, rating and maintenance, and 3) supply processed cross-sectional and longitudinal data on serial MRIs and DaTscans for the Project focused on predicting phenoconversion, and share these data with the research community. This latter aim includes providing cross-sectional and longitudinal data to the Laboratory of Neuroimaging (LONI) for sharing with outside investigators. All images will be anonymized and directly downloadable from the LONI website. Language will be developed on the NAPS2 and LONI websites to guide outside investigators interested in these data. This clinical dataset will be freely downloadable along with the images for researchers who do not require genetic information for their analyses.

摘要：NAPS2神经影像核心 RBD上北美前驱突触联盟的神经影像核心， 阶段2（NAPS2）将确保应用最新技术并进行创新分析 使用技术。神经影像芯将由大脑成像中的领导者指导 具有丰富经验的神经退行性疾病支持多站点项目的成像需求。 许多核心领导者都与小睡调查员合作，就RBD和 突触核酸。神经影像团队内的先前经验和合作将确保 对NAPS2的成像支持的平稳过渡2。 RBD的先前成像研究很少，并且通常具有 很小，回顾性或单一站点调查。我们提供初步数据以支持所有 成像方式将在协议中使用并演示方法的音质 建议的。我们将前瞻性地收集和评估300多个超过300的多模式MRI和DATSCAN成像数据 RBD的参与者在两个时间点纵向，并采用了支持该项目的创新方法 推进领域。该核心有几个创新方面，包括：1）多壳和 合理的高分辨率DMRI和RS-FMRI数据收集的多频段成像采集协议 采集时间，在多个站点之间进行协调，2）用多回声梯度回声定量铁载荷 （GRE）MRI使用定量敏感性映射和R2*弛豫测定法，3）定量神经元素 使用磁化转移对比度的层层层和底座 具有自动图像处理和高可重现性的神经素素敏感的MRI（NM-MRI）方法 4）使用半自动化处理来提供标准化和 统一的区域到后环和Z分数数据。神经影像核心的目的是：1）建立和 维护参与站点的协调MRI和DATSCAN SPECT采集协议，2）操作 MRI和DATSCAN的标准化质量控制计划，包括持续的图像质量监控，评级 和维护，以及3）有关串行MRI和DATSCAN的处理的横截面和纵向数据 对于该项目，重点是预测现场转化，并与研究界共享这些数据。 后一个目的包括向神经影像实验室提供横截面和纵向数据 （LONI）与外部调查员分享。所有图像将是匿名化的，可直接从中下载 LONI网站。语言将在NAPS2和LONI网站上开发，以指导外部 对这些数据感兴趣的调查人员。该临床数据集将与图像一起免费下载 对于不需要遗传信息进行分析的研究人员。